Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biol Blood Marrow Transplant 2014 Dec;20(12):2062-6
Date
07/22/2014Pubmed ID
25046834Pubmed Central ID
PMC4291068DOI
10.1016/j.bbmt.2014.07.014Scopus ID
2-s2.0-84912100424 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
We conducted a pilot study evaluating double umbilical cord blood transplantation (dCBT) after myeloablative conditioning with fludarabine and busulfan 3.2 mg/kg i.v. × 4, followed by total lymphoid irradiation at 400 cGy (FluBu4/TLI) for any indicated hematological disorder for patients without a suitable donor. Twenty patients with predominantly high-risk disease underwent dCBT according to protocol. The regimen was well tolerated, with mucositis as the primary observed toxicity (n = 19). The cumulative incidence of neutrophil engraftment was 89% (95% confidence interval [CI], 64% to 97%), with a median time to recovery of 16 days (range, 12 to 31 days). All evaluable patients with neutrophil engraftment achieved complete donor chimerism by day 40. The cumulative incidence of grades III and IV acute graft-versus-host disease (GVHD) at day 100 was 10% (95% CI, 2% to 27%), and the cumulative incidence of chronic GVHD was 35% (95% CI, 16% to 55%) by the end of the study. At 1 year, the cumulative incidence of treatment-related mortality (TRM) was 35% (95% CI, 16% to 55%). The leading cause of nonrelapse mortality was acute GVHD (n = 4), followed by graft failure (n = 2) and chronic GVHD (n = 1). TRM was significantly associated with a pretransplantation hematopoietic cell transplantation-specific comorbidity index score ≥ 3 (P = .005). At 1 year, disease relapse occurred in 6 patients and overall survival was 40% (95% CI, 19% to 60%). We conclude that FluBu4/TLI is an adequate preparative regiment before dCBT, providing high engraftment rates and relatively early neutrophil recovery. The best survival outcomes were seen in patients without significant comorbidities before transplantation, and outcomes are comparable to previously published dCBT studies.
Author List
Abedin S, Peres E, Levine JE, Choi S, Yanik G, Couriel DRAuthor
Sameem Abedin MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Acute DiseaseAdolescent
Adult
Aged
Busulfan
Child
Child, Preschool
Chronic Disease
Cord Blood Stem Cell Transplantation
Disease-Free Survival
Female
Follow-Up Studies
Graft Survival
Graft vs Host Disease
Hematologic Diseases
Humans
Incidence
Infant
Infant, Newborn
Male
Middle Aged
Myeloablative Agonists
Neoplasms
Pilot Projects
Survival Rate
Time Factors
Transplantation Conditioning
Vidarabine
Whole-Body Irradiation
